论文部分内容阅读
1例48岁女性患者因右肺小细胞肺癌并脑转移行依托泊苷+卡铂方案化疗和全脑放射治疗。后因肿瘤进展，在行第4周期化疗时联合特瑞普利单抗治疗（240 mg静脉滴注，1次/21 d），未再进行放射治疗。化疗7个疗程后采用特瑞普利单抗单药治疗。特瑞普利单抗第5次给药后第2天，患者出现明显乏力、恶心、呕吐、反复发热等症状。实验室检查示促肾上腺皮质激素及皮质醇降低（1.5 μg/L，3.9 μg/L），催乳素增高（127.6 μg/L），甲状腺功能正常。行垂体磁共振检查排除肿瘤占位，考虑为特瑞普利单抗所致垂体炎，给予氢化可的松替代治疗后症状消失。应用特瑞普利单抗9次后，患者出现多尿、烦渴、夜尿增多，实验室检查示尿比重、尿渗透浓度降低（1.010，132 mmol/L）。考虑尿崩症为特瑞普利单抗相关垂体炎表现，停用特瑞普利单抗，给予去氨加压素治疗后症状改善。治疗3个月余，尿崩症症状消失，停用去氨加压素，未再复发。“,”A 48-year-old female patient received chemotherapy with etoposide and carboplatin combined with whole brain radiotherapy for small cell lung cancer located in the right lung with brain metastasis. An IV infusion of toripalimab 240 mg once per 21 days in the 4th cycle of chemotherapy was combined due to tumor progression, and no radiotherapy was given again. After 7 courses of chemotherapy, the patient received monotherapy with toripalimab. On the 2nd day after the 5th administration of toripalimab, the patient developed obvious fatigue, nausea, vomiting, and repeated fever. Laboratory tests showed decreased corticotropin and cortisol (1.5 μg/L, 3.9 μg/L), increased prolactin (127.6 μg/L), and normal thyroid function. Excluding tumor occupation by pituitary magnetic resonance imaging, it was considered as hypophysitis caused by toripalimab. Symptoms disappeared after hydrocortisone replacement therapy was given. After the 9th administration of toripalimab, the patient developed polyuria, thirst, and nocturia. Laboratory tests showed decreased urine specific gravity and urine osmolality (1.010, 132 mmol/L). Diabetes insipidus as the manifestation of hypophysitis caused by toripalimab was considered. The above symptoms were improved after discontinuation of toripalimab and administration of desmopressin. After more than 3 months of the treatment, symptoms of diabetes insipidus disappeared. Then desmopressin was discontinued and diabetes insipidus did not recur.